The whole process of generating disease-specific subnetworks is described in Figure 2. Note that everything in Figure 2 applies to finding drug-specific subnetworks.
DNA-In CRISPR is an innovative transfection reagent that simplifies and accelerates genome editing using large plasmids and difficult-to-transfect cells for life science researchers generating disease models.
The successful application of induced pluripotent stem cell (iPSC) technology in murine models of human diseases, and in generating disease-free autologous cells from patient samples offers considerable potential for development of personalized cell based therapies of monogenic disorders [1] [9].
Alteration in gene expression regulation provides a potential mechanism for generating disease susceptibility.
These mechanisms are represented by differential gene expression profiles, generating disease developmental stages that vary from latent to aggressive forms.
Top-down synthetic epigenetic approaches have already made a big contribution in generating disease model cell lines.
Recent studies have been successful in generating disease-specific induced pluripotent stem cells (iPSCs) from a variety of neurodevelopmental and neurodegenerative disorders, providing useful in vitro models.
Generating disease-models based on literature data is a very natural and efficient way to better understand and summarize the current knowledge about different high-level systems.
In addition to generating disease-specific iPSCs from patients, the use of gene-modifying nucleases to create hESCs harboring specific genetic mutations may be a forward approach towards studying human disease pathogenesis [ 86].
The classical ways of generating disease models in zebrafish via forward genetics based on random mutagenesis or morpholino suppression have been an important adjunct to disease gene discovery and validation.
